N-(1,3-苯并二氧-5-甲基)-2-氯乙酰胺 | 40023-03-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: N-(1,3-苯并二氧-5-甲基)-2-氯乙酰胺
• 中文别名: N-(1,3-苯并二氧代l-5-基甲基)-2-氯乙酰胺
• 英文名称: N-(benzo[d][1,3]dioxol-5-ylmethyl)-2-chloroacetamide
• 英文别名: N-(1,3-benzodioxol-5-ylmethyl)-2-chloroacetamide；N-benzo[1,3]dioxol-5-ylmethyl-2-chloro-acetamide；chloro-acetic acid piperonylamide；Chlor-essigsaeure-piperonylamid；N-benzo[1,3]dioxol-5-yl-methyl-2-chloro-acetamide；N-benzo[1,3]dioxol-5-ylmethyl-2-chloro-acetamide
• CAS: 40023-03-8
• 化学式: C₁₀H₁₀ClNO₃
• mdl: MFCD02317455
• 分子量: 227.647
• InChiKey: PLXGAUGZSOPIIG-UHFFFAOYSA-N

物化性质

• 熔点：
  113-114 °C(Solv: chloroform (67-66-3))
• 沸点：
  440.5±45.0 °C(Predicted)
• 密度：
  1.361±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2932999099

SDS

Name:	n-(1 3-Benzodioxol-5-ylmethyl)-2-chloroacetamide 97% Material Safety Data Sheet
Synonym:
CAS:	40023-03-8

Section 1 - Chemical Product MSDS Name:n-(1 3-Benzodioxol-5-ylmethyl)-2-chloroacetamide 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
40023-03-8	N-(1,3-Benzodioxol-5-ylmethyl)-2-chlor	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 40023-03-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: beige
Odor: odorless
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 91.4 - 93.8 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H10ClNO3
Molecular Weight: 227.65

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 40023-03-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N-(1,3-Benzodioxol-5-ylmethyl)-2-chloroacetamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 40023-03-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 40023-03-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 40023-03-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(1,3-苯并二氧-5-甲基)-2-氯乙酰胺 在 三乙胺 作用下， 以 甲醇 为溶剂， 反应 6.67h， 生成 5-(N-(3,4-methylenedioxybenzyl)carbamoyl)-3-(4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazole 2-oxide
  参考文献：
  名称：

  3,4-二芳基-异恶唑-5-羧酰胺的有效合成及其抗增殖特性

  摘要：

  3,4-二芳基异恶唑-5-羧酰胺6，热休克蛋白抑制剂的结构类似物，是由中间3,4-二芳基-5-酰胺基异恶唑啉N-氧化物的简单可伸缩的重排作用得到5。与此相反，3,4-二芳基-5-（乙氧基羰基）异恶唑啉N-氧化物的碱催化的再成环9意外得到5-羟基-1,2-恶嗪-6-酮17。

  DOI：

  10.1002/ejoc.201900643
• 作为产物：
  描述：

  piperonal-(Z)-oxime 在 sodium amalgam 、 sodium carbonate 、 溶剂黄146 作用下， 生成 N-(1,3-苯并二氧-5-甲基)-2-氯乙酰胺
  参考文献：
  名称：

  Mannich; Kuphal, Chemische Berichte, 1912, vol. 45, p. 319

  摘要：

  DOI：

文献信息

• Inducible nitric oxide synthase dimerization inhibitors
  申请人：Gahman C. Timothy

  公开号：US20060116515A1

  公开（公告）日：2006-06-01

  The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula: wherein T, X, and Y are independently selected from the group consisting of CR 4 , N, NR 4 , S, and O; U is selected from the group consisting of CR 10 and N; V is selected from the group consisting of CR 4 and N; W and W′ are independently selected from the group consisting of CH 2 , CR 7 R 8 , NR 9 , O, N(O), S(O) q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.

  本发明涉及化合物和方法，用作一氧化氮合酶的抑制剂。本发明的某些化合物具有以下结构式： 其中T、X和Y分别选自CR 4 、N、NR 4 、S和O组成的群；U选自CR 10 和N组成的群；V选自CR 4 和N组成的群；W和W′分别选自CH 2 、CR 7 R 8 、NR 9 、O、N(O)、S(O) q 和C(O)组成的群；n、m和p分别是从0到5的整数；q为0、1或2；其他取代基如本文所定义。本发明的其他化合物具有如本文所定义的结构式。本文还公开了包含本发明化合物的药物组合物。
• An Old Story in the Parallel Synthesis World: An Approach to Hydantoin Libraries
  作者：Andrey V. Bogolubsky、Yurii S. Moroz、Olena Savych、Sergey Pipko、Angelika Konovets、Maxim O. Platonov、Oleksandr V. Vasylchenko、Vasyl V. Hurmach、Oleksandr O. Grygorenko

  DOI：10.1021/acscombsci.7b00163

  日期：2018.1.8

  An approach to the parallel synthesis of hydantoin libraries by reaction of in situ generated 2,2,2-trifluoroethylcarbamates and α-amino esters was developed. To demonstrate utility of the method, a library of 1158 hydantoins designed according to the lead-likeness criteria (MW 200–350, cLogP 1–3) was prepared. The success rate of the method was analyzed as a function of physicochemical parameters

  开发了一种通过原位生成的2,2,2-三氟乙基氨基甲酸酯与α-氨基酯反应平行合成乙内酰脲文库的方法。为了证明该方法的实用性，准备了根据铅样标准（MW 200–350，cLogP 1-3）设计的1158个乙内酰脲文库。分析了该方法的成功率与产品理化参数的关系，发现该方法可以被认为是用于铅导向合成的工具。通过合理设计，使用开发的方法进行平行合成，计算机模拟和体外筛选相结合的方法，发现了一种含乙内酰脲的超微摩尔主要分子，可作为Aurora激酶A抑制剂。
• Synthesis of annulated heterocyclic systems based on 4-CF3- or 4-CHF2-3-cyano-(1H)-pyridine-2-thiones
  作者：L. A. Rodinovskaya、A. E. Fedorov、A. M. Shestopalov、P. A. Belyakov、K. G. Nikishin

  DOI：10.1007/s11172-013-0321-9

  日期：2013.10

  A simple and convenient preparative method for the synthesis of 3-cyano-4-difluoro- and -trifluoromethylpyridine-2(1H)-thiones was developed. During studies of synthetic potential of these compounds, approaches to the synthesis of a number of annulated heterocyclic systems were suggested.

  开发了一种简便的合成方法，用于合成3-氰基-4-二氟和-三氟甲基吡啶-2(1H)-硫醇。在研究这些化合物的合成潜力过程中，提出了一系列环合杂环体系的合成方法。
• [EN] GPR139 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR GPR139
  申请人：BLACKTHORN THERAPEUTICS INC

  公开号：WO2021127459A1

  公开（公告）日：2021-06-24

  Compounds are provided that modulate the GPR139 receptor, compositions containing the same, and to methods of their preparation and use for treatment of a malcondition wherein modulation of the GPR139 receptor is medically indicated or beneficial. Such compounds have the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R4, R5, R9, R10, Q6, Q7, and Q12 are as defined herein.

  提供了调节GPR139受体的化合物，含有这些化合物的组合物，以及它们的制备和用于治疗GPR139受体调节在医学上指示或有益的疾病的方法。这些化合物具有以下结构的化学式（I）：或其药学上可接受的异构体、拉克酸盐、水合物、溶剂化合物、同位素或盐，其中R1、R4、R5、R9、R10、Q6、Q7和Q12如本文所定义。
• Lead Optimization and Structure–Activity Relationship Studies on Myeloid Ecotropic Viral Integration Site 1 Inhibitor
  作者：Bengisu Turgutalp、Merve Uslu、Sinem Helvacioglu、Mohammad Charehsaz、Enise Ece Gurdal、Wolfgang Sippl、Fatih Kocabas、Mine Yarim

  DOI：10.1021/acs.jmedchem.1c00972

  日期：2021.10.14

  site (MEIS) inhibitor, MEISi-1, to induce murine and human HSC expansion ex vivo and in vivo. In this work, we performed lead optimization on MEISi-1 by synthesizing 45 novel analogues. Structure–activity relationship studies revealed the significance of a para-methoxy group on ring A and a hydrophobic moiety at the meta position of ring B. Obtained biological data were supported by inhibitor docking and

  我们之前的研究结果报道了骨髓嗜嗜性病毒整合位点 1 (MEIS1) 转录因子在心脏再生和造血干细胞 (HSC) 调节中的关键作用。MEIS1 作为药理抑制背景下的一个有希望的靶点，我们鉴定了一种有效的髓系亲嗜性病毒整合位点 (MEIS) 抑制剂 MEISi-1，可在体外和体内诱导小鼠和人类 HSC 扩增。在这项工作中，我们通过合成 45 种新型类似物对 MEISi-1 进行了先导优化。构效关系研究揭示了环A上的对甲氧基和环B间位的疏水部分的重要性. 获得的生物学数据得到了抑制剂对接和分子动力学模拟研究的支持。11 种化合物被描述为强效抑制剂，证明对 MEIS1 和靶基因Meis1、Hif-1 α 和p21具有更好的抑制作用。其中，4h、4f和4b是最有效的抑制剂。预测的药代动力学特性满足药物相似性标准。此外，化合物对人皮肤成纤维细胞既没有细胞毒性，也没有致突变性。